年龄对转移性结直肠癌一线序贯与联合化疗疗效及早期死亡的影响
本文为XELAVIRI III期试验的年龄亚组分析,比较氟嘧啶联合贝伐珠单抗后序贯升级伊立替康(A组)与起始即联合化疗(B组)在转移性结直肠癌患者中的疗效。结果显示起始联合化疗对年轻患者获益更明显,而≥75岁患者获益有限,且该人群在接受含伊立替康联合贝伐珠单抗方案时60天死亡风险值得关注。
要点
- 年轻转移性结直肠癌患者从起始联合化疗中获益更明显。
- ≥75岁患者接受起始联合化疗的总体生存获益有限。
- ≥75岁患者含伊立替康联合贝伐珠单抗方案60天死亡风险值得关注。
核心结论
- 氟嘧啶、伊立替康联合贝伐珠单抗方案相比序贯治疗算法并未显著改善≥75岁患者的结局。
- ≥75岁患者在接受含伊立替康联合化疗加贝伐珠单抗治疗时似乎存在相关的60天死亡风险。
研究设计与样本
- XELAVIRI研究为III期试验,共421例随机化转移性结直肠癌患者。
- 患者按年龄分为<65岁、65-74岁和≥75岁三个队列。
- 生存终点采用Kaplan-Meier法、log-rank检验和Cox回归分析,客观缓解与60天死亡率采用卡方检验。
主要发现
- 疗效分析提示年轻转移性结直肠癌患者从起始联合化疗中获益更明显。
- ≥75岁患者从起始联合化疗中获益有限,尤其在总体生存方面。
- 421例随机化患者中13例(3.1%)在治疗开始后60天内死亡,<65岁为1.6%、65-74岁为2.8%、≥75岁为5.2%(p=0.26)。
- 在接受起始联合治疗的患者中,60天死亡率与年龄显著相关,≥75岁患者最高达8.7%(p=0.027)。
- 在接受序贯治疗的患者中,60天死亡率与年龄无显著关联(p=0.63)。
关键数值与推荐
- 60天死亡率总体为13/421(3.1%),年龄分层为<65岁1.6%、65-74岁2.8%、≥75岁5.2%,p=0.26。
- 起始联合治疗组60天死亡率与年龄显著相关,≥75岁患者最高达8.7%,p=0.027。
- 序贯治疗组60天死亡率与年龄无显著关联,p=0.63。
临床怎么用
- 对≥75岁转移性结直肠癌患者,起始即联合氟嘧啶、伊立替康与贝伐珠单抗相比序贯治疗未显示显著结局改善。
- 对≥75岁患者考虑含伊立替康联合贝伐珠单抗方案时,需关注其60天死亡风险并权衡治疗选择。
局限性
- 本文为III期试验的亚组分析,按年龄分层后各队列样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The XELAVIRI study compared application of fluoropyrimidine (FP) and bevacizumab (Bev) followed by sequential escalation to irinotecan (Iri), FP and Bev (arm A) to upfront combination therapy with FP, Iri and Bev (arm B) in patients with metastatic colorectal cancer (mCRC). To elucidate the impact of age on survival, we evaluated efficacy and early mortality in the underlying trial. METHODS: Patients were stratified for age in three cohorts (<65 years, 65-74 years and ≥75 years). Survival end-points were expressed by the Kaplan-Meier method and compared by log-rank testing and Cox regression. Objective response and 60-day mortality were evaluated by chi-square testing. RESULTS: The efficacy analyses suggest more substantial benefit from upfront combination chemotherapy in younger patients with mCRC. Elderly patients (≥75 years) derived limited benefit from upfront combination chemotherapy, particularly in terms of overall survival. Of 421 randomised patients, 13 patients (3.1%) died within 60 days after treatment initiation with the highest prevalence in elderly patients (1.6% < 65 years, 2.8% 65-74 years and 5.2% ≥ 75 years, p = 0.26). The frequency of 60-day mortality was significantly associated with age (with a maximum of 8.7% in patients aged ≥75 years) in patients undergoing upfront combination therapy (p = 0.027) but not in patients receiving sequential treatment (p = 0.63). CONCLUSION: Combination therapy with FP, Iri and Bev does not substantially improve the outcome of patients aged ≥75 years as compared with sequential treatment algorithm. These patients appear to be at a relevant risk for 60-day mortality under Iri-based combination chemotherapy plus Bev.
引用
- Kurreck A, Heinemann V, Fischer von Weikersthal L, et al. Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study). Eur J Cancer. 2020. PMID: 32750502. doi:10.1016/j.ejca.2020.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。